Bradley Pharmaceuticals Overview
- Latest Deal Type
- Financing Rounds
Want detailed data on 3M+ companies?
What you see here scratches the surfaceRequest a free trial
Want to dig into this profile?
We’ll help you find what you needLearn more
|Publication ID||Patent Title||Status||First Filing Date||Technology (CPC)||Citations|
|US-20040156874-A1||Can be applied to the affected dermal site formulated as a cream, lotion, solution, gel, lacquer, ointment, foam, or any vehicle capable of applying urea directly to the affected site.||Abandoned||11-Feb-2003||00000000||0|
|US-20040156870-A1||Administering urea to the affected area of human skin either before, after or with a topical anti-inflammatory drug.||Abandoned||11-Feb-2003||000000000||00|
|US-20040127512-A1||Administering methscopolamine bromide for therapy of symptoms of non-constipated irritable bowel syndrome (ibs) and diarrhea-predominant ibs||Abandoned||30-Dec-2002||00000000000||0|
|US-20040018221-A1||A mixture of urea and vitamin e for treating dry skin, dermatitis, eczema, debridement; cosmetics, skin disorders||Abandoned||28-Nov-2001||0000000000||0|
|US-20030138466-A1||Topical products with antioxidant formulations to prevent uv-induced carcinogenesis and photoaging and to modulate desquamatory skin disorders; comprising 40 wt-% urea, 0.1-20 wt-% antioxidant, balance excipients||Abandoned||28-Nov-2001||A61Q19/007||00|
|Name||Title||Board Seat||Contact Info|
|Daniel Glassman||President & Chief Executive Officer & Founder|
|Brent Lenczycki||Chief Financial Officer & Vice President|